The 8th National Conference on Colposcopy and Cervix Pathology (CSCCP) successfully concluded, July 10^th, 2022.

Renowned gynecologists, maternal and child health experts, cytopathologists, epidemiologists and basic research experts from China and abroad gathered in this CSCP congress to share disciplinary knowledge and exchange learning in a comprehensive manner, presenting a high-quality, high -standard academic feast.

With the theme of "Promoting Refined management of lower genital tract lesions", the congress held cross-disciplinary discussions and debates on hotspots of lower genital tract lesions, such as young women's forum, postmenopausal women's forum, special populations forum, vulvovaginal and perianal lesions forum, and new technologies for cervical cancer prevention and treatment forum. Through special lectures, expert discussions and off-site Q&A sessions, ideas and advances were presented, showing the latest research trends and academic frontier achievements in the field of cervical cancer prevention and treatment in China.

After that, Professor Wei Lihui, Director of CSCCP, Professor Kong Beihua of Qilu Hospital of Shandong University, Professor Qie Mingrong of West China Second University Hospital of Sichuan University, Professor Zhang Youzhong of Qilu Hospital of Shandong University, Professor Wang Xinyu of the First Affiliated Hospital of Zhejiang University School of Medicine, Professor Lin Bei of Shengjing Hospital of China Medical University and Professor Luo Xiping of Guangdong Maternal and Child Health Hospital, jointly opened the "Cervical Cancer Prevention and Treatment Science Popularization Capacity Enhancement Project". All the experts expressed the importance of popularization of Scinence, and hoped that more doctors would devote themselves to the popularization of cervical cancer prevention and treatment, strive to improve the popularization ability of doctors, so as to continuously convey the scientific information of cervical cancer prevention and treatment to the public.

DALTONbio made presentation in the main forum of CSCCP conference: Refined management strategy for HPV primary screening positive.

On July 9, in the main forum of CSCCP conference, DALTONbio invited Prof. Wei Lihui from Peking University People's Hospital to preside and Prof. Wang Xinyu from the First Affiliated Hospital of Zhejiang University School of Medicine to bring the first satellite session titled "Refined Management Strategies for HPV Primary Screening Positive".

At present, cervical cancer is still a serious threat to women's health and is increasing and getting younger every year. Cervical cancer screening is still an effective means to prevent HPV infection, while refined triage management of HPV can more effectively reduce women's risk of developing cervical cancer and is a means to reduce the incidence of cervical cancer.

Professor Wang Xinyu from the First Affiliated Hospital of Zhejiang University School of Medicine pointed out in the satellite meeting that HPV DNA detection is the main screening manner for cervical cancer, and the domestic review guidelines have also been issued to regulate HPV primary screening reagents. HPV positive groups can be managed by HPV 16/18 typing, viral load and p16/Ki-67 dual staining. CINdi欣媂 fully automated p16/Ki-67 dual staining system by DALTONbio demonstrates its superiority in HPV-positive group triage management with its more objective and sensitive performance, while a large amount of clinical data confirms its value in HPV-positive group triage and identification of high-risk groups.

Prof. Li-Hui Wei concluded: HPV DNA detection for primary screening is becoming more and more common, and the combination of HPV16/18 typing, p16/Ki-67 dual staining and viral load can effectively achieve triage and management of HPV positive groups for efficient cervical cancer screening.